Hopes for single-dose Hepatitis C drug fade

February 9, 2015 8:30 PM

3 0

Hopes for single-dose Hepatitis C drug fade

Shares of Regulus fall but company, analysts still see promise

LOS ANGELES (MarketWatch) — Shares of Regulus Therapeutics took it on the chin Monday after the biopharmaceutical company reported spotty results in tests for a drug designed to cure Hepatitis C with a single dose.

Read more

To category page

Loading...